Kit ELISA sandwich Vascular Endothelial cell Growth Factor A (Rt VEGF-A) (rat): quantitative assay of Rt VEGF-A in serum, plasma or cell culture medium.
Kit ELISA sandwich Vascular Endothelial cell Growth Factor A (Rt VEGF-A) (rat): quantitative assay of Rt VEGF-A in serum, plasma or cell culture medium. The test recognizes only the natural and recombinant forms of Rt VEGF-A.
Method principle: This ELISA solid phase sandwich test (immuno-enzymatic dose) measures the amount of target bound between a pair of matched antibodies. A specific target antibody is pre-adsorbed into the wells of the supplied microplate. Samples, standards or controls are added to these wells and bind to immobilized antibodies (capture antibodies). The sandwich is formed by adding the second antibody (detection antibody), then a substrate solution reacts with the enzyme-antibodies-target complex to produce a measurable signal. The intensity of this signal is directly proportional to the concentration of the target present in the original sample.
Rigorous validation: Each batch manufactured from this ELISA kit is checked for criteria such as sensitivity, specificity, accuracy and reproducibility from one batch to another (see the package leaflet for more information on validation).
VEGF (vascular endothelial growth factor), which is a homodimer glycoprotein with disulfide bridges involved in 45 kDa angiogenesis, promotes tumour progression and metastases. VEGF has various effects on vascular endothelium, including the ability to promote endothelial cell viability, mitogenesis, chemotaxia and vascular permeability. VEGF's family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and PIGF. The VEGF and its receptor system have proven to be the fundamental regulators of cell signaling of langenogenicity. Most tumours have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine associated with this process. To date, 5 different VEGF isoforms have been described. These isoforms are generated following an alternative splicing from a single VEGF gene. These isoforms bind to two tyrosine-kinase flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2) receptors, which express almost exclusively on endothelial cells. VEGF and its high affinity binding receptors, tyrosine kinases FLK1 and FLT1, would be important for the development of the embryonic vascular system. Studies have shown that an alternately spliced form of FLT1 produces a soluble protein, called sFLT1, which binds vascular endothelial growth factor with high affinity, acting as an inhibitor in angiogenesis. High levels of VEGF are associated with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammapathy, skin changes), also known as Crow-Fukase syndrome, which affects several organs of the body.
Sensitivity
Sensitivity of dosage: 2 pg/ml.
Measurement range
Dosing range: 0.82-200 pg/ml.
Duration of dosing
Total duration of dosing: 4 h 45 min.
Reproducibility
Intradose variation coefficient < 10%, interdose < 12%.
Technical specifications
| General |
| Brand | Invitrogen |
| Supplier ref. (Fisher Scientific) | 15485393 |
| Specifications |
| Accession number | P16612 |
| Dose range | 0.82-200 pg/ml |
| Sensitivity of the dosage | 2 pg/ml |
| Calibration range | 2 pg/ml to 200 pg/ml |
| Dose | ELISA solid-phase sandwich |
| Conjugate | Biotin |
| Product type | Kit ELISA |
| Protein family | Chemiokine & receptors |
| Type of sample | Serum, Surnatant, Surnatant |
| Specificity | This ELISA kit shows no cross-reactivity with the following tested cytokines: rat CNI-2, CNIC-3, CNTF, fractalkin, IL-1 alpha, IL-1 beta, IL-4, IL-6, IL-10, GM-CSF, IFN-gamma, leptine, Lix, MCP-1, MIP-3 alpha, beta-NGF, TIMP-1, TNF-alpha. |
| Sufficient for | 96 dosages |
| Target species | Rat |
| For use with (application) | ELISA, protein dosage, protein biology, cancerology, immunology, neuroscience, neurobiology, protein detection, protein analyses |
| For use with (equipment) | Colorimetric microplate reader |
| Genetic identification (Enter) | 83785 |
| Gene symbol(s) | VEGF-A,VEGF164,VPF,Vegf |
| Coefficient of inter-dose variation | < 12 % |
| Coefficient of intra-dose variation | < 10 % |
| Contents of kits | 96-well pre-coated plate, Standard, Dose diluent concentrate, Biotinylated detection antibody, Wash pad, Chromogen, Stop solution, Adhesive plate covers, Adhesive plate covers |
| Marker or dye | HRP |
| Quantity | 96 tests |
| Regulatory status | RUO |
| Research disciplines | Oncology |
| Synonym | VEGF-A, VEGF164, VPF, Vegf |
| Target | Rat |
| Test time | 1 h 20 min |
| Physical characteristics |
| Volume of sample | Plasma, 50 μl; serum, 50 μl; supernatant, 100 μl |
| Storage and shipping |
| Storage conditions | 2°C to 8°C |
| Total duration of dosing | 4 h 45 min |
Origin and customs
| Manufacturer ref. | ERVEGFA |
|---|
| Country of origin | United States |
|---|
| HS customs code | 3002 15 00 00 |
|---|
A question or a specific configuration?
Contact us for a quote.